AVI BioPharma Announces Presentations on Exon Skipping Drug AVI-4658 for Treatment of Duchenne Muscular Dystrophy at Internation
July 16 2010 - 1:00PM
Marketwired
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs,
today announced upcoming presentations on AVI-4658, the Company's
exon skipping therapy for the treatment of Duchenne muscular
dystrophy, at the XII International Congress on Neuromuscular
Diseases taking place July 17-22, 2010 in Naples, Italy. The
presentations will highlight results from Study 28, the recently
completed Phase 1b/2 clinical trial of AVI-4658.
Stephen B. Shrewsbury, M.D., Senior Vice President and Chief
Medical Officer at AVI, will present on Sunday, July 18 during
poster session 5B: Muscular Dystrophies: State of the Art in
Diagnosis & RNA Modulation for Duchenne Muscular Dystrophy. Dr.
Shrewsbury's presentation is titled "Current Progress with the
Systemic Administration Trial of AVI-4658, a Novel
Phosphorodiamidate Morpholino Oligomer (PMO) Skipping Dystrophin
Exon 51 in Duchenne Muscular Dystrophy (DMD)."
In addition, Dr. Francesco Muntoni, Professor of Pediatric
Neurology and Head of the Dubowitz Neuromuscular Centre at the UCL
Institute of Child Health, London, England will present on Monday,
July 19 during a late-breaking poster session. His presentation is
titled "Systemic Administration of AVI-4658 a Phosphorodiamidate
Morpholino Oligomer (PMO) Restores Dystrophin Expression in
Selected Duchenne Muscular Dystrophy (DMD) Boys in a Dose Dependent
Manner."
Both presentations will be posted on the AVI BioPharma website
the afternoon of Monday, July 19.
AVI-4658 is AVI's lead drug candidate being developed as a
systemically administered treatment for a substantial subgroup of
patients with Duchenne muscular dystrophy (DMD), a genetic muscle
wasting disease caused by failure to produce dystrophin.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of
novel RNA-based therapeutics for rare and infectious diseases, as
well as other select disease targets. Applying pioneering
technologies developed and optimized by AVI, we are able to target
a broad range of diseases and disorders through distinct RNA-based
mechanisms of action. Unlike other RNA-based approaches, our
technologies can be used to directly target both messenger RNA
(mRNA) and precursor messenger RNA (pre-mRNA) to either
down-regulate (inhibit) or up-regulate (promote) the expression of
targeted genes or proteins. By leveraging our highly differentiated
RNA antisense-based technology platform, we have built a pipeline
of potentially transformative therapeutic agents, including a
clinical stage Duchenne muscular dystrophy candidate and
anti-infective candidates for influenza and hemorrhagic fever
viruses. For more information, visit www.avibio.com.
"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995: The statements that are not historical facts
contained in this release are forward-looking statements that
involve risks and uncertainties, including, but not limited to, the
results of research and development efforts, the results of
preclinical and clinical testing, the effect of regulation by the
FDA and other agencies, the impact of competitive products, product
development, commercialization and technological difficulties, and
other risks detailed in the company's Securities and Exchange
Commission filings.
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From May 2024 to Jun 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2023 to Jun 2024